| Title |
Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
|
|---|---|
| Published in |
Clinical Cancer Research, January 2018
|
| DOI | 10.1158/1078-0432.ccr-17-2092 |
| Pubmed ID | |
| Authors |
Giovanna Rossi, Zhaomei Mu, Alfred W. Rademaker, Laura K. Austin, Kimberly S. Strickland, Ricardo Lima Barros Costa, Rebecca J. Nagy, Vittorina Zagonel, Timothy J. Taxter, Amir Behdad, Firas H. Wehbe, Leonidas C. Platanias, William J. Gradishar, Massimo Cristofanilli |
| Abstract |
Liquid biopsy provides a real-time assessment of metastatic breast cancer (MBC). We evaluated the utility of combining circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) to predict prognosis in MBC. We conducted a retrospective study of 91 patients with locally advanced and MBC. CTCs were enumerated by CellSearch; the plasma-based assay was performed utilizing Guardant360TM and the survival analysis using Kaplan-Meier curves. 84 patients had stage IV cancer, 7 had no metastases. Eighty patients had CTCs analysis: median number 2 (0-5612). 232/277 (84%) blood samples had mutations. The average ctDNA fraction was 4.5% (0-88.2%) and number of alterations 3 (0-27); the most commonly mutated genes: TP53 (52%), PIK3CA (40%), ERBB2 (20%). At the time of analysis 36 patients (39.6%) were dead. The median follow-up for CTCs was 9 months; for ctDNA 9.9 months. For CTCs and ctDNA respectively, PFS was 4.2 and 5.2 months and OS was 18.7 and 21.5 months. There was a statistically significant difference in PFS and OS for baseline CTCs < 5 versus CTCs ≥ 5 (p = 0.021 and p = 0.0004 respectively); % ctDNA < 0.5 versus ≥ 0.5 p = 0.003 and p = 0.012); number of alterations < 2 versus ≥ 2 (p = 0.059 borderline and p= 0.0015). A significant association by Fisher's exact test was found between the number of alterations and the % ctDNA in the baseline sample p < 0.0001). The study demonstrated that liquid biopsy is an effective prognostic tool. |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 35% |
| Spain | 1 | 5% |
| Italy | 1 | 5% |
| Russia | 1 | 5% |
| United Kingdom | 1 | 5% |
| Belgium | 1 | 5% |
| Unknown | 8 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 55% |
| Scientists | 5 | 25% |
| Practitioners (doctors, other healthcare professionals) | 3 | 15% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 185 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 185 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 27 | 15% |
| Researcher | 26 | 14% |
| Student > Bachelor | 18 | 10% |
| Student > Master | 17 | 9% |
| Other | 16 | 9% |
| Other | 34 | 18% |
| Unknown | 47 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 52 | 28% |
| Biochemistry, Genetics and Molecular Biology | 39 | 21% |
| Agricultural and Biological Sciences | 12 | 6% |
| Engineering | 11 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Other | 12 | 6% |
| Unknown | 54 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2021.
All research outputs
#1,139,736
of 25,340,976 outputs
Outputs from Clinical Cancer Research
#768
of 13,216 outputs
Outputs of similar age
#26,729
of 453,159 outputs
Outputs of similar age from Clinical Cancer Research
#19
of 162 outputs
Altmetric has tracked 25,340,976 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,216 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 453,159 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 162 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.